Endevica’s novel peptidomimetics overcome the current limitations of small molecules, antibodies and other modalities to treat conditions safely, effectively and with minimal side effects.
Cancer cachexia drug, TCMCB07, has started an innovative P2 trial in 2025, redefining the standard of care in oncology.
Weight loss drug, 710GO, reduces weight of obese non-human primates by 11.7% over 15 weeks without GLP-1-like side effects.